Recently, the results of the large-scale, multicenter ambispective cohort study (FLYING study) on Fulaimei (PEG-Loxenatide Injection), a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) of Hansoh Pharmaceutical, were published in the internationally renowned medical journal MedComm (IF: 10.7) [1]. This study confirmed that long-term use of Fulaimei in patients with type 2 diabetes mellitus (T2DM) significantly reduces the risk of major adverse cardiovascular events (MACE) by 32%.
The FLYING study is the world's first large-scale real-world study to assess the cardiovascular benefits of GLP-1RA specifically in the Chinese population, its findings provide robust evidence to support Fulaimei’s significant cardiovascular advantages for T2DM patients.
Managing cardiovascular complications and related mortality has always been a major challenge in diabetes treatment. This FLYING study was conducted across six tertiary hospitals in three cities in China. A large-language model was used for retrospective screening, and a total of over 12,000 patients with T2DM, all of whom had pre-existing cardiovascular diseases or cardiovascular risk factors, were included.
The study compared cardiovascular event rates over a four-year follow-up period between the Fulaimei treated group (treatment group) and the non-incretin antidiabetic drugs treated group (control group).
The results demonstrated that the risk of major adverse cardiovascular events in the Fulaimei trated group was 32% lower than that in the control group, and the incidences of first non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death were all significantly lower than those in the control group [1].
The FLYING study is the first to provide compelling evidence that Fulaimei not only helps lower blood sugar level but also reduces the risk of adverse cardiovascular events. It provides a superior option for the long-term treatment of T2DM who have cardiovascular diseases or cardiovascular risk factors. Its significant cardiovascular benefits can contribute to the improvement of patient quality of life, reduced additional healthcare costs, and extended survival.
References: [1]MedComm (2020) . 2025 Feb 13;6(2):e70094.
(Source of image materials: The website of MedComm）
